Press release issued by Fredun Pharmaceuticals Limited.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals reported strong Q1 FY26 results, with total income up 52% YoY to ₹119.86 Cr and net profit rising nearly 64% YoY to ₹6.77 Cr from ₹4.13 Cr. EBITDA grew 62% to ₹16.99 Cr, with margins improving 88 basis points to 14.18%, reflecting better operating efficiency. Diluted EPS jumped 63% to ₹14.33. The company also secured a credit rating upgrade to IVR BBB/Stable (from IVR BBB-/Stable) on facilities worth ₹139.64 Cr. Additionally, its wholly-owned subsidiary FRPL acquired a controlling stake in One Pet Stop, marking its entry into the organized pet care segment. Management highlighted an order book of over ₹200 Cr and a generics portfolio of 1,200+ products under registration, supporting growth visibility.
Strong earnings growth, margin expansion, and a credit rating upgrade signal improving financial health and may attract investor interest. The pet care acquisition diversifies revenue streams beyond traditional pharma, though execution risk in a new segment remains. Overall, the results are positive for shareholder sentiment.